

4 December 2020
EFPIA Japan

Yoshiaki Aono appointed new Vice Chair of EFPIA Japan

TOKYO—4 December 2020— EFPIA Japan announced today that Yoshiaki Aono (Representative Director, Chairman and President of Nippon Boehringer Ingelheim Co., Ltd.) has been appointed the new Vice Chair of EFPIA Japan, effective 1 December 2020 with terms until 31 December 2021. This appointment is associated with the resignation of Kazunari Tsunaba.

Together with Takahiko Iwaya (President, Sanofi K.K.) who continues to serve in his position of Vice Chair, Yoshiaki Aono will support Heike Prinz (President and Representative Director, Bayer Yakuhin, Ltd.), the Chair of EFPIA Japan.

“As the impact of COVID-19 continues to be felt across the world, EFPIA Japan remains committed to joining forces to fight against the pandemic through innovation and cross-border industry-government-academia collaboration. While the global and Japanese healthcare environments are undergoing rapid change, we will continue to make contributions to debates for finding solutions that will support sustainability of the healthcare system”, says Yoshiaki Aono.

EFPIA Japan Board Members as of 1 December 2020

Chair	Heike Prinz	(Bayer Yakuhin, Ltd.)	
Vice Chairs	Takahiko Iwaya	(Sanofi K.K.)	
	Yoshiaki Aono	(Nippon Boehringer Ingelheim Co., Ltd.)	New
Board of Directors	Ole Mølskov Bech	(Novo Nordisk Pharma Ltd.)	
	Stefan Woxström	(AstraZeneca K.K.)	
	Paul Lirette	(GlaxoSmithKline K.K.)	
	Leo Lee	(Novartis Pharma K.K.)	New
	Alexandre De Muralt	(Merck Biopharma Co., Ltd.)	
	Kanako Kikuchi	(UCB Japan Co., Ltd.)	
Director General	Yasuhiro Nishimi	(Nippon Boehringer Ingelheim Co., Ltd.)	



European Federation of Pharmaceutical
Industries and Associations

About EFPIA Japan (<http://efpia.jp/>)

Established in April 2002, EFPIA Japan represents 21 R&D-based European pharmaceutical companies operating in Japan. In 2019, combined sales from the member companies accounted for roughly 23% of the pharmaceutical market in Japan. The mission of EFPIA Japan is to “Contribute to healthcare and patients in Japan through the early introduction of innovative medicines and vaccines”. EFPIA Japan aims to strengthen dialogue with decision-makers in order to improve Japanese healthcare for all.

About EFPIA (European Federation of Pharmaceutical Industries and Associations)

(<http://www.efpia.eu>)

EFPIA, EFPIA Japan’s partner organisation, is headquartered in Brussels and represents the pharmaceutical industry operating in Europe. Through its direct membership of 36 national associations and 39 leading pharmaceutical companies, EFPIA provides the voice of companies committed to researching, developing and bringing new medicines to improve health and quality of life around the world.

Contact:

Yuko Kidoguchi

EFPIA Japan Messaging & Communications Committee

1-6-5 Marunouchi Chiyoda-ku, Tokyo 100-8268

Bayer Holding Ltd.

Tel: 03-6266-7757

Email: yuko.kidoguchi@bayer.com

EFPIA Japan

ThinkPark Tower, 2-1-1, Osaki, Shinagawa-ku, Tokyo 141-6017, Japan

Tel: +81-3- 6417-2032

Fax: +81-3- 6685-4870

Yoshiaki Aono



Current Position

Representative Director, Chairman and President of Nippon Boehringer Ingelheim Co., Ltd.
Representative Director Chairman of Boehringer Ingelheim Seiyaku Co., Ltd
Representative Director Chairman of Boehringer Ingelheim Animal Health Japan Co., Ltd

Born in 1957 in Hyogo Prefecture

Graduated from the Faculty of Engineering at Shizuoka University in March 1979

Professional Experience

Dec 2020	Vice Chair of EFPIA Japan
Sep 2020	Representative Director, Chairman and President of Nippon Boehringer Ingelheim Co., Ltd. Representative Director Chairman of Boehringer Ingelheim Seiyaku Co., Ltd Representative Director Chairman of Boehringer Ingelheim Animal Health Japan Co., Ltd
Jan 2020	Representative Director, President of Human Pharma Business Unit of Nippon Boehringer Ingelheim Co., Ltd.
Jun 2012	President and Representative Director of Nippon Boehringer Ingelheim Co., Ltd.
May 2012	Joined Nippon Boehringer Ingelheim Co., Ltd. as a Director
Apr 1979	Joined Nihon Ciba-Geigy K.K Experienced Sales, Marketing and Corporate Planning related functions at Nihon Ciba-Geigy as well as Novartis Pharma KK due to the merger with Sandoz K.K

As of December 2020